

Fiscal Note

State of Alaska
2016 Legislative Session

Bill Version:	CSSB 142(L&C)
Fiscal Note Number:	1
(S) Publish Date:	2/17/2016

Identifier: SB142-DCCED-DOI-01-29-16
 Title: INSURANCE FOR ANTI-CANCER MEDICATION
 Sponsor: GIESSEL
 Requester: (S) Labor and Commerce

Department: Department of Commerce, Community and
 Economic Development
 Appropriation: Insurance Operations
 Allocation: Insurance Operations
 OMB Component Number: 354

Expenditures/Revenues

Note: Amounts do not include inflation unless otherwise noted below. (Thousands of Dollars)

	FY2017	Included in	Out-Year Cost Estimates				
	Appropriation	Governor's	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
	Requested	FY2017					
		Request					
OPERATING EXPENDITURES	FY 2017	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Personal Services							
Travel							
Services							
Commodities							
Capital Outlay							
Grants & Benefits							
Miscellaneous							
Total Operating	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Fund Source (Operating Only)

None							
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Positions

Full-time							
Part-time							
Temporary							

Change in Revenues

--	--	--	--	--	--	--	--

Estimated SUPPLEMENTAL (FY2016) cost: 0.0 *(separate supplemental appropriation required)*
(discuss reasons and fund source(s) in analysis section)

Estimated CAPITAL (FY2017) cost: 0.0 *(separate capital appropriation required)*
(discuss reasons and fund source(s) in analysis section)

ASSOCIATED REGULATIONS

Does the bill direct, or will the bill result in, regulation changes adopted by your agency? No
 If yes, by what date are the regulations to be adopted, amended or repealed?

Why this fiscal note differs from previous version:

Not applicable, initial version.

Prepared By:	Lori Wing-Heier, Director	Phone:	(907)465-2560
Division:	Insurance	Date:	01/29/2016 01:47 PM
Approved By:	Catherine Reardon, Director	Date:	01/29/16
Agency:	Division of Administrative Services, DCCED		

FISCAL NOTE ANALYSIS**STATE OF ALASKA
2016 LEGISLATIVE SESSION****Analysis**

SB 142 amends AS 21.42 to prohibit health care insurers that provide coverage for anti-cancer medications from requiring a higher copayment, deductible, or coinsurance amount for patient-administered medication than for medications administered by a health care provider. The bill also prohibits affected insurers from offsetting the costs of compliance with the revised statute by increasing copayments, deductibles or coinsurance amounts for the anti-cancer medications, or by reclassifying benefits for anti-cancer medications.

The Division of Insurance does not anticipate fiscal impact from this legislation.